JP2008505190A - 骨の形成と再構築のための組成物および方法 - Google Patents
骨の形成と再構築のための組成物および方法 Download PDFInfo
- Publication number
- JP2008505190A JP2008505190A JP2007527363A JP2007527363A JP2008505190A JP 2008505190 A JP2008505190 A JP 2008505190A JP 2007527363 A JP2007527363 A JP 2007527363A JP 2007527363 A JP2007527363 A JP 2007527363A JP 2008505190 A JP2008505190 A JP 2008505190A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- protein
- lrp5
- bone
- lrp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims 475
- 230000011164 ossification Effects 0.000 title claims 291
- 239000000203 mixture Substances 0.000 title claims 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract 567
- 108090000623 proteins and genes Proteins 0.000 claims abstract 567
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims abstract 468
- 102000013814 Wnt Human genes 0.000 claims abstract 203
- 108050003627 Wnt Proteins 0.000 claims abstract 203
- 210000000988 bone and bone Anatomy 0.000 claims abstract 113
- 108010006519 Molecular Chaperones Proteins 0.000 claims abstract 103
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims abstract 76
- 101150021503 Mesd gene Proteins 0.000 claims abstract 61
- 230000003993 interaction Effects 0.000 claims abstract 29
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims abstract 22
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims 522
- 150000002632 lipids Chemical class 0.000 claims 489
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 451
- 230000010072 bone remodeling Effects 0.000 claims 287
- 108090000765 processed proteins & peptides Proteins 0.000 claims 228
- 102000005962 receptors Human genes 0.000 claims 186
- 108020003175 receptors Proteins 0.000 claims 186
- 102000004196 processed proteins & peptides Human genes 0.000 claims 154
- 235000000346 sugar Nutrition 0.000 claims 138
- 239000000126 substance Substances 0.000 claims 122
- 102000004895 Lipoproteins Human genes 0.000 claims 120
- 108090001030 Lipoproteins Proteins 0.000 claims 120
- 125000000623 heterocyclic group Chemical group 0.000 claims 120
- 102000039446 nucleic acids Human genes 0.000 claims 120
- 108020004707 nucleic acids Proteins 0.000 claims 120
- 150000007523 nucleic acids Chemical class 0.000 claims 120
- 229930186217 Glycolipid Natural products 0.000 claims 115
- 150000003384 small molecules Chemical class 0.000 claims 115
- 230000004936 stimulating effect Effects 0.000 claims 115
- 125000004122 cyclic group Chemical group 0.000 claims 114
- 229920001184 polypeptide Polymers 0.000 claims 114
- 102000003886 Glycoproteins Human genes 0.000 claims 113
- 108090000288 Glycoproteins Proteins 0.000 claims 113
- 230000001737 promoting effect Effects 0.000 claims 108
- 241000124008 Mammalia Species 0.000 claims 98
- 206010028980 Neoplasm Diseases 0.000 claims 82
- 230000005856 abnormality Effects 0.000 claims 82
- 208000020084 Bone disease Diseases 0.000 claims 81
- 239000012634 fragment Substances 0.000 claims 79
- 150000008163 sugars Chemical class 0.000 claims 76
- 206010017076 Fracture Diseases 0.000 claims 71
- 206010061363 Skeletal injury Diseases 0.000 claims 69
- 230000012010 growth Effects 0.000 claims 63
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 62
- 208000010392 Bone Fractures Diseases 0.000 claims 56
- 239000005557 antagonist Substances 0.000 claims 54
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims 52
- 230000001225 therapeutic effect Effects 0.000 claims 52
- 230000027455 binding Effects 0.000 claims 50
- 102000015735 Beta-catenin Human genes 0.000 claims 48
- 108060000903 Beta-catenin Proteins 0.000 claims 48
- 230000003834 intracellular effect Effects 0.000 claims 47
- 238000009825 accumulation Methods 0.000 claims 40
- 239000003112 inhibitor Substances 0.000 claims 38
- 230000037361 pathway Effects 0.000 claims 24
- 108010001831 LDL receptors Proteins 0.000 claims 23
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 23
- 238000007634 remodeling Methods 0.000 claims 22
- 102000051172 Axin Human genes 0.000 claims 19
- 108700012045 Axin Proteins 0.000 claims 19
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims 19
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims 19
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 19
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims 19
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 claims 19
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 claims 19
- 101100210337 Drosophila melanogaster wntD gene Proteins 0.000 claims 19
- 108091007911 GSKs Proteins 0.000 claims 19
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 19
- 102000000479 TCF Transcription Factors Human genes 0.000 claims 19
- 108010016283 TCF Transcription Factors Proteins 0.000 claims 19
- 101150109862 WNT-5A gene Proteins 0.000 claims 19
- 101150019524 WNT2 gene Proteins 0.000 claims 19
- 102000052547 Wnt-1 Human genes 0.000 claims 19
- 108700020987 Wnt-1 Proteins 0.000 claims 19
- 102000052556 Wnt-2 Human genes 0.000 claims 19
- 108700020986 Wnt-2 Proteins 0.000 claims 19
- 102000043366 Wnt-5a Human genes 0.000 claims 19
- 108700020483 Wnt-5a Proteins 0.000 claims 19
- -1 polar lipids Chemical class 0.000 claims 19
- 230000035755 proliferation Effects 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 16
- 238000007918 intramuscular administration Methods 0.000 claims 16
- 238000007912 intraperitoneal administration Methods 0.000 claims 16
- 238000001990 intravenous administration Methods 0.000 claims 16
- 238000007911 parenteral administration Methods 0.000 claims 16
- 239000004031 partial agonist Substances 0.000 claims 16
- 238000012216 screening Methods 0.000 claims 16
- 238000007920 subcutaneous administration Methods 0.000 claims 16
- 238000011200 topical administration Methods 0.000 claims 16
- 240000007113 Rumex obtusifolius Species 0.000 claims 15
- 230000002159 abnormal effect Effects 0.000 claims 15
- 230000006378 damage Effects 0.000 claims 13
- 230000004156 Wnt signaling pathway Effects 0.000 claims 12
- 108091005475 signaling receptors Proteins 0.000 claims 12
- 102000035025 signaling receptors Human genes 0.000 claims 12
- 230000000638 stimulation Effects 0.000 claims 12
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 11
- 238000005728 strengthening Methods 0.000 claims 11
- 230000033228 biological regulation Effects 0.000 claims 10
- 238000010276 construction Methods 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 108091005703 transmembrane proteins Proteins 0.000 claims 4
- 102000035160 transmembrane proteins Human genes 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000008298 dragée Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000002002 slurry Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 239000006188 syrup Substances 0.000 claims 3
- 235000020357 syrup Nutrition 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000010478 bone regeneration Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 244000090689 Rumex alpinus Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract 5
- 230000008485 antagonism Effects 0.000 abstract 4
- 230000003305 autocrine Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 230000003076 paracrine Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000963 osteoblast Anatomy 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000002449 bone cell Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/849,067 US8637506B2 (en) | 2003-09-22 | 2004-05-19 | Compositions and methods for bone formation and remodeling |
| PCT/US2005/017199 WO2005115354A2 (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505190A true JP2008505190A (ja) | 2008-02-21 |
| JP2008505190A5 JP2008505190A5 (OSRAM) | 2008-07-03 |
Family
ID=35451375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527363A Pending JP2008505190A (ja) | 2004-05-19 | 2005-05-18 | 骨の形成と再構築のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8637506B2 (OSRAM) |
| EP (3) | EP1758562B1 (OSRAM) |
| JP (1) | JP2008505190A (OSRAM) |
| CN (1) | CN101316627A (OSRAM) |
| CA (6) | CA2771951C (OSRAM) |
| IL (1) | IL179241A (OSRAM) |
| WO (1) | WO2005115354A2 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536816A (ja) * | 2005-03-18 | 2008-09-11 | エンゾー バイオケム，インコーポレイテッド | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 |
| JP2010537950A (ja) * | 2006-11-14 | 2010-12-09 | エンゾー セラピューティクス， インコーポレイテッド | 骨形成および骨リモデリングのための組成物および方法 |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770461B1 (en) * | 1998-10-23 | 2004-08-03 | Genome Therapeutics Corporation | High bone mass gene of 11q13.3 |
| US6780609B1 (en) * | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
| US20040221326A1 (en) * | 2001-05-11 | 2004-11-04 | Philip Babij | Transgenic animal model of bone mass modulation |
| US7416849B2 (en) * | 2001-05-11 | 2008-08-26 | Oscient Pharmaceuticals Corporation | HBM variants that modulate bone mass and lipid levels |
| US20030219793A1 (en) * | 2002-10-04 | 2003-11-27 | Carulli John P. | High bone mass gene of 11q13.3 |
| US7485460B2 (en) * | 2003-05-21 | 2009-02-03 | Tulane University Health Sciences Center | Enhanced growth of adult stem cells with Dkk-1 |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US20100041599A1 (en) | 2006-11-14 | 2010-02-18 | Dakai Liu | Compositions and methods for bone formation, bone remodeling and toxin protection |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US20120178697A9 (en) * | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US9052324B2 (en) * | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| EP2150270A4 (en) * | 2007-04-30 | 2011-09-28 | Univ Washington | METHODS AND COMPOSITIONS FOR TREATING CANCER |
| WO2008144659A2 (en) * | 2007-05-18 | 2008-11-27 | Board Of Regents, The University Of Texas System | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers |
| CN101951954A (zh) * | 2007-11-02 | 2011-01-19 | 诺瓦提斯公司 | 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法 |
| US8715941B2 (en) | 2007-11-16 | 2014-05-06 | Arca Biopharma, Inc. | Antibodies to LRP6 |
| US8716243B2 (en) * | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| US8703708B2 (en) | 2009-03-18 | 2014-04-22 | The Brigham And Women's Hospital, Inc. | Agents and methods for tissue repair and regeneration |
| AR076668A1 (es) | 2009-05-12 | 2011-06-29 | Pfizer | Anticuerpos especificos para dkk-1 y sus usos |
| EA201291181A1 (ru) | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
| CA2798432A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| JP5972283B2 (ja) * | 2011-01-11 | 2016-08-17 | フェイト セラピューティクス，インコーポレイテッド | 新規のＷｎｔ組成物およびそのような組成物の治療的使用 |
| KR20140091031A (ko) | 2011-11-04 | 2014-07-18 | 노파르티스 아게 | 저밀도 지단백질-관련 단백질 6 (lrp6) - 반감기 연장제 구축물 |
| CN103966229A (zh) * | 2014-05-09 | 2014-08-06 | 中山大学 | bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用 |
| EP3191526B1 (en) | 2014-09-12 | 2023-02-22 | The Board of Trustees of the Leland Stanford Junior University | Wnt signaling agonist molecules |
| CN106367517A (zh) * | 2016-09-28 | 2017-02-01 | 湖北工业大学 | 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用 |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| JP7317016B2 (ja) | 2017-12-19 | 2023-07-28 | スロゼン オペレーティング， インコーポレイテッド | 抗ｌｒｐ５／６抗体及び使用方法 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| EP4398990A4 (en) * | 2021-09-08 | 2025-07-16 | Baylor College Medicine | METHODS AND COMPOSITIONS FOR IMMUNE REGULATION BY DICKKOPF-1 |
| CN115309402B (zh) * | 2022-07-13 | 2023-10-24 | 国网江苏省电力有限公司信息通信分公司 | 一种可量化差异的异构执行程序集合构成方法及装置 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092015A2 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS562623A (en) * | 1979-06-21 | 1981-01-12 | Matsushita Electric Industrial Co Ltd | Electrode |
| EP0639889B1 (en) * | 1993-08-19 | 1999-09-15 | Advanced Micro Devices, Inc. | Low voltage fully differential operational amplifiers |
| US7244577B2 (en) | 1997-04-15 | 2007-07-17 | Merck & Co., Inc. | Method of screening for modulator of LRP5 activity |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU3510200A (en) * | 1999-03-05 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| WO2001073019A1 (de) | 2000-03-29 | 2001-10-04 | Max-Planck-Gesellschaft | Raumform von tpr-strukturmotiv enthaltenden polypeptiden mit chaperon-bindungsfunktion, deren kristalle und verbindungen zur inhibierung derartiger polypeptide |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| CA2465499A1 (en) | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| US20050084494A1 (en) | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US20120178697A9 (en) | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US9046537B2 (en) * | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
| US7838252B2 (en) | 2005-02-17 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject having an anthrax toxin mediated condition |
-
2004
- 2004-05-19 US US10/849,067 patent/US8637506B2/en not_active Expired - Lifetime
-
2005
- 2005-05-18 WO PCT/US2005/017199 patent/WO2005115354A2/en not_active Ceased
- 2005-05-18 CA CA2771951A patent/CA2771951C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772029A patent/CA2772029C/en not_active Expired - Lifetime
- 2005-05-18 EP EP05751764A patent/EP1758562B1/en not_active Expired - Lifetime
- 2005-05-18 CN CNA2005800243835A patent/CN101316627A/zh active Pending
- 2005-05-18 EP EP16000780.3A patent/EP3150255A1/en not_active Withdrawn
- 2005-05-18 EP EP11184755.4A patent/EP2409732B1/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771941A patent/CA2771941C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771940A patent/CA2771940C/en not_active Expired - Lifetime
- 2005-05-18 JP JP2007527363A patent/JP2008505190A/ja active Pending
- 2005-05-18 CA CA2567023A patent/CA2567023C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772033A patent/CA2772033C/en not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179241A patent/IL179241A/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092015A2 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536816A (ja) * | 2005-03-18 | 2008-09-11 | エンゾー バイオケム，インコーポレイテッド | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 |
| JP2010537950A (ja) * | 2006-11-14 | 2010-12-09 | エンゾー セラピューティクス， インコーポレイテッド | 骨形成および骨リモデリングのための組成物および方法 |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL179241A (en) | 2016-04-21 |
| EP2409732B1 (en) | 2016-04-06 |
| CA2772029C (en) | 2016-05-17 |
| CA2772029A1 (en) | 2005-12-08 |
| CA2772033A1 (en) | 2005-12-08 |
| CA2771951A1 (en) | 2005-12-08 |
| US20050196349A1 (en) | 2005-09-08 |
| US8637506B2 (en) | 2014-01-28 |
| CA2567023C (en) | 2012-07-03 |
| EP2409732A1 (en) | 2012-01-25 |
| WO2005115354A3 (en) | 2007-09-13 |
| EP1758562B1 (en) | 2012-12-05 |
| IL179241A0 (en) | 2007-03-08 |
| CA2771940A1 (en) | 2005-12-08 |
| EP1758562A4 (en) | 2009-07-22 |
| CA2771941C (en) | 2015-03-31 |
| CA2771941A1 (en) | 2005-12-08 |
| CA2771951C (en) | 2014-07-08 |
| CA2772033C (en) | 2016-05-17 |
| EP1758562A2 (en) | 2007-03-07 |
| CA2771940C (en) | 2016-01-12 |
| WO2005115354A2 (en) | 2005-12-08 |
| US20060198791A2 (en) | 2006-09-07 |
| EP3150255A1 (en) | 2017-04-05 |
| CN101316627A (zh) | 2008-12-03 |
| CA2567023A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2772029C (en) | Compositions and methods for bone formation and remodeling | |
| JP4993623B2 (ja) | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 | |
| Matsuoka et al. | p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. | |
| Semënov et al. | Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6 | |
| Kwon et al. | Myocilin is a modulator of Wnt signaling | |
| US7541431B2 (en) | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto | |
| US20090047276A1 (en) | Methods for increasing cell or tissue regeneration in a vertebrate subject | |
| US20090312253A1 (en) | Methods of effecting Wnt signaling through Dkk structural analysis | |
| Mahapatra et al. | The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion | |
| Narita et al. | A Wnt3a variant participates in chick apical ectodermal ridge formation: distinct biological activities of Wnt3a splice variants in chick limb development | |
| Orioli et al. | Rac3-induced neuritogenesis requires binding to Neurabin I | |
| US20090136482A1 (en) | Drug target protein and target gene, and screening method | |
| Huh et al. | Muscle function and dysfunction in health and disease | |
| HK1150962A (en) | Sclerostin and the inhibition of wnt signaling and bone formation | |
| Ai | The Consequences of LRP5 Mutations on the Skeleton |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080514 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110418 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110712 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110720 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110812 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110907 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110914 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120116 |